Chief Operating Officer Alan Raffensperger to leave Sobi™
Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that the company and Alan Raffensperger, Chief Operating Officer (COO), have come to the agreement that Alan Raffensperger will leave the company to pursue other opportunities. Alan Raffensperger has led the commercial organisation responsible for launching Sobi’s haemophilia products in Europe as well as the expansion of Sobi’s global brands Orfadin and Kineret in Europe and North America. In addition to leading the commercial teams, Alan Raffensperger has also been responsible for Sobi's Partner Products